FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity MOST POPULAR FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... June 6, 2023 ¿El azúcar provoca cáncer? September 20, 2022 Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... June 2, 2022 Our 10 top tips to help you talk about cancer April 24, 2023 Load more HOT NEWS Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer Tumor Signatures May Help Explain Global Differences in Kidney Cancer Rates What Is Intuitive Eating and How Can It Help During Cancer? Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer
